Validating CaMKK2 as a Rational Treatment Target for Bipolar Disorder [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description Bipolar disorder is a disabling, chronic mental illness that profoundly impairs the ability of affected individuals to function in daily life. Existing treatments for bipolar disorder are inadequate and lack the necessary efficacy and tolerability required for long-term therapy. This project will validate the enzyme, CaMKK2, as a rational treatment target for bipolar disorder, which will guide the development of more effective and safer drugs to improve patient outcomes.

Funding Amount $688,175

Funding Scheme Ideas Grants

Chief Investigator Dr John Scott

Notes Ideas Grants